Newly Diagnosed AA/AO/AOA with 1p/19q Codeletion : RTOG 1071

PHASE III INGERGROUP STUDY OF RADIOTHERAPY vs TEMOZOLOMIDE ALONE vs RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE (IRB# 23210)

Phase III Intergroup Study of Radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma CODEL -RTOG

• Newly diagnosed and ≤3 months from surgical diagnosis
• Histological confirmation of anaplastic glioma (oligodendroglioma, mixed, orastrocytoma [WHO grade III]), as determined by pre-registration central pathology review. Tumor must also be co-deleted for 1p and 19q.

The purpose of this study is to determine whether there is a survival advantage for those who receive concomitant temozolomide and RT followed by adjuvant temozolomide (Stupp regimen), over that observed in patients treated with RT alone (control).

• Arm 1: RT and concurrent temozolomide followed by adjuvant temozolomide x 6 cycles
• Arm 2: RT Alone x 6 weeks
• Arm 3: Temozolomide x 12 cycles

Surasak Phuphanich, MD, FAAN
Director, Neuro-oncology Program
phuphanich@cshs.orG
Phone: (310) 423-8100

Heather Chen
Program Coordinator
heather.chen@cshs.org
(310) 248-6773